The exploratory study for the drug-predictive markers of TS-1 in metastatic or recurrent breast cancer; Translational biomarker study of SELECT BC trial

The exploratory study for the drug-predictive markers of TS-1 in metastatic or recurrent breast cancer; Translational biomarker study of SELECT BC trial - SELECT BC - the better drug predictive marker analysis (SELECT BC-EURECA)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014245

Enrollment

140

Registered

2014-06-12

Start date

2014-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic or recurrent breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Institutional review board (IRB) approval for research and transportation of breast cancer samples 2) Availability to obtain surgical specimen or core needle biopsy sample of breast cancer

Exclusion criteria

Exclusion criteria: 1) Patients not adequate for participation in this study at doctors' discretion. 2) Patients not obtained informed consentnot obtained informed consent

Design outcomes

Primary

Measure	Time frame
Correlation between the bio-marker and clinical efficacy, i.e. PFS: progression free survival, of each patient who has participated in SELECT BC trial	—

Secondary

Measure	Time frame
Correlation between the bio-marker and clinical efficacy, i.e. TTF:Time to Treatment Failure, OS:Overall survival, and DCR:Disease control rate, of each patient who has participated in SELECT BC trial	—

Countries

Japan

Contacts

Public ContactAkira Yamao

Public Health Research Foundation Comprehensive Support Project for Oncology Research

support@csp.or.jp03-5287-2636

Outcome results